Is Sunil Healthcare overvalued or undervalued?

As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19, which suggests that while the stock is expensive relative to earnings, it may offer growth potential at a reasonable price.
In comparison to its peers, Sunil Healthcare's PE ratio is higher than Sun Pharma Industries, which is considered expensive at 35.17, but lower than Divi's Laboratories, which is very expensive at 71.11. Additionally, Cipla, rated attractive, has a significantly lower PE ratio of 22.33, indicating that Sunil Healthcare may not be the best value in its sector. The company's recent stock performance has lagged behind the Sensex, particularly over the past year, where it has declined by 11.93% compared to a 4.62% increase in the index, further supporting the view that it is fairly valued at this time.